HCW Biologics terminates Wugen license, regains ex vivo rights to HCW9201/9206 at no cost

HCW Biologics Inc.

Company exercised option to terminate exclusive worldwide license from Wugen for ex vivo rights to HCW9201 and HCW9206; regained rights at no cost.
Retained nonrefundable upfront license fee including 2.2 million shares of Wugen common stock.
Recent data in Science Advances suggests HCW9206 may reduce CAR-T production costs and improve therapeutic efficacies.
Company plans to commercialize the reagents through partners focused on CAR-T and NK-cell therapies.

item 1.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

HCW Biologics Inc. terminated License with Wugen Inc. (effective 2026-05-21).

Action: termination
Agreement: license
Counterparty: Wugen Inc.
Effective: 2026-05-21

Exact text from the filing

On May 27, 2026, HCW Biologics Inc. (the “Company”) issued a press release announcing that on May 21, 2026, the Company elected to exercise its option to terminate the exclusive worldwide license agreement with Wugen Inc. (the “License”) for ex vivo rights to the Company’s molecules HCW9201 and HCW9206.

View on SEC.gov

Browse all material agreements →

HCW Biologics Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-025336

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.